Rhea M. Shields

Array ( [id] => 19354099 [patent_doc_number] => 12054528 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-06 [patent_title] => Co-agonists of the GLP-1 and amylin receptors [patent_app_type] => utility [patent_app_number] => 18/084088 [patent_app_country] => US [patent_app_date] => 2022-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 183 [patent_figures_cnt] => 183 [patent_no_of_words] => 31621 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18084088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19930361 [patent_doc_number] => 12303554 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Use of ultrarapid acting insulin [patent_app_type] => utility [patent_app_number] => 18/077742 [patent_app_country] => US [patent_app_date] => 2022-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 28 [patent_no_of_words] => 22312 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18077742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18733578 [patent_doc_number] => 11802301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-31 [patent_title] => Compositions and methods for peptide production [patent_app_type] => utility [patent_app_number] => 18/063064 [patent_app_country] => US [patent_app_date] => 2022-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 26 [patent_no_of_words] => 18256 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 351 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18063064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18281863 [patent_doc_number] => 20230097335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => FIBROBLAST GROWTH FACTOR 1 (FGF1) MUTANT PROTEINS THAT SELECTIVELY ACTIVATE FGFR1B TO REDUCE BLOOD GLUCOSE [patent_app_type] => utility [patent_app_number] => 18/061182 [patent_app_country] => US [patent_app_date] => 2022-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18061182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18266710 [patent_doc_number] => 20230087952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid [patent_app_type] => utility [patent_app_number] => 17/988271 [patent_app_country] => US [patent_app_date] => 2022-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14788 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17988271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18322469 [patent_doc_number] => 20230120597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY [patent_app_type] => utility [patent_app_number] => 17/980990 [patent_app_country] => US [patent_app_date] => 2022-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15586 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17980990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18916731 [patent_doc_number] => 11879001 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-23 [patent_title] => Conjugate comprising an IL-2 moiety [patent_app_type] => utility [patent_app_number] => 18/052495 [patent_app_country] => US [patent_app_date] => 2022-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 102218 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18311755 [patent_doc_number] => 20230115655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION [patent_app_type] => utility [patent_app_number] => 18/049445 [patent_app_country] => US [patent_app_date] => 2022-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18049445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18340100 [patent_doc_number] => 20230132049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => ANTIBODIES BINDING TO CD30 AND CD3 [patent_app_type] => utility [patent_app_number] => 17/938523 [patent_app_country] => US [patent_app_date] => 2022-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31181 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19830945 [patent_doc_number] => 20250082731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-13 [patent_title] => TRANSDERMAL INSULIN FORMULATIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/028036 [patent_app_country] => US [patent_app_date] => 2022-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18147983 [patent_doc_number] => 20230021840 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => USE OF GP73 INHIBITOR IN PREPARATION OF MEDICINE FOR TREATING DIABETES [patent_app_type] => utility [patent_app_number] => 17/930144 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13267 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389894 [patent_doc_number] => 20230158112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => Targeting gamma-delta T Cells in Obesity and Cachexia [patent_app_type] => utility [patent_app_number] => 17/929209 [patent_app_country] => US [patent_app_date] => 2022-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077381 [patent_doc_number] => 20220402993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => INSULIN-TRANSFERRIN FUSION PROTEIN AND ITS PRODRUG, PROINSULIN-TRANSFERRIN, FOR OVERCOMING INSULIN RESISTANCE [patent_app_type] => utility [patent_app_number] => 17/895638 [patent_app_country] => US [patent_app_date] => 2022-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17895638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413156 [patent_doc_number] => 11667689 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Insulin-Fc fusion proteins and methods of use to treat cancer [patent_app_type] => utility [patent_app_number] => 17/814285 [patent_app_country] => US [patent_app_date] => 2022-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 21873 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18228934 [patent_doc_number] => 20230067928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => METHODS FOR PROGNOSING AND PREVENTING METASTATIC LIVER DISEASE [patent_app_type] => utility [patent_app_number] => 17/869948 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22728 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17869948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18251551 [patent_doc_number] => 20230078590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DIABETES AND RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/813383 [patent_app_country] => US [patent_app_date] => 2022-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17813383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958515 [patent_doc_number] => 20220339095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => METHODS FOR DELIVERING ETANERCEPT PREPARATIONS INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE [patent_app_type] => utility [patent_app_number] => 17/863322 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17863322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18177058 [patent_doc_number] => 20230037787 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => METHODS AND COMPOSITIONS RELATING TO HOT-START, ONE-STEP, REVERSE TRANSCRIPTION-COUPLED PCR [patent_app_type] => utility [patent_app_number] => 17/862825 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17862825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19989638 [patent_doc_number] => 20250127860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-24 [patent_title] => SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/572577 [patent_app_country] => US [patent_app_date] => 2022-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18572577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18427647 [patent_doc_number] => 11672848 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells [patent_app_type] => utility [patent_app_number] => 17/852623 [patent_app_country] => US [patent_app_date] => 2022-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 48796 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17852623 [rel_patent_id] =>[rel_patent_doc_number] =>)